Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Low-dose Trifluridine/Tipiracil With Bevacizumab in Refractory Metastatic Colorectal Cancer: a Multicenter, Single-arm, Phase 2 Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT07085169
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:32.901506+00:00
Published At
2025-07-25T00:00:00+00:00
Record Updated At
2025-07-25
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Colo-rectal Cancer", "Third-line and Beyond Therapy", "TAS 102", "Bevacizumab"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-07-25"
protocolSection.identificationModule.nctId
"NCT07085169"
protocolSection.identificationModule.officialTitle
"Low-dose Trifluridine/Tipiracil With Bevacizumab in Refractory Metastatic Colorectal Cancer: a Multicenter, Single-arm, Phase 2 Study"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Colo-rectal Cancer (protocolSection.conditionsModule.conditions)
  • Third-line and Beyond Therapy (protocolSection.conditionsModule.conditions)
  • TAS 102 (protocolSection.conditionsModule.conditions)
  • Bevacizumab (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.